Evidence map›Paper›PMID 34444906›Full record

ArticleNutrients2021

Saccharin and Sucralose Protect the Glomerular Microvasculature In Vitro against VEGF-Induced Permeability.

Emmanuella Enuwosa, Lata Gautam, Linda King, Havovi Chichger

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. AI-driven discovery of blood xenobiotic biomarkers in neovascular age-related macular degeneration using iterative random forests.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Observational
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Emmanuella EnuwosaBiomedical Research Group, Faculty of Science & Engineering, School of Life Sciences, Anglia Ruskin University, Cambridge CB1 1PT, UK.
Lata GautamForensic Science Research Group, Faculty of Science & Engineering, School of Life Sciences, Anglia Ruskin University, Cambridge CB1 1PT, UK.
Linda KingBiomedical Research Group, Faculty of Science & Engineering, School of Life Sciences, Anglia Ruskin University, Cambridge CB1 1PT, UK.
Havovi ChichgerBiomedical Research Group, Faculty of Science & Engineering, School of Life Sciences, Anglia Ruskin University, Cambridge CB1 1PT, UK.ORCID 0000-0002-8549-7583
Anglia Ruskin University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD) has become a global health concern, with about 40% of people living with type 1 and type 2 diabetes mellitus developing DKD. Upregulation of vascular endothelial growth factor (VEGF) in the kidney is a significant pathology of DKD associated with increased glomerular vascular permeability. To date, however, current anti-VEGF therapies have demonstrated limited success in treating DKD. Recent studies have shown that artificial sweeteners exhibit anti-VEGF potential. The aim of this study was therefore to assess the effects of aspartame, saccharin, and sucralose on VEGF-induced leak using an in vitro model of the glomerular endothelium. Saccharin and sucralose but not aspartame protected against VEGF-induced permeability. Whilst the sweeteners had no effect on traditional VEGF signalling, GC-MS analysis demonstrated that the sweetener sucralose was not able to enter the glomerular endothelial cell to exert the protective effect. Chemical and molecular inhibition studies demonstrated that sweetener-mediated protection of the glomerular endothelium against VEGF is dependent on the sweet taste receptor, T1R3. These studies demonstrate the potential for sweeteners to exert a protective effect against VEGF-induced increased permeability to maintain a healthy endothelium and protect against vascular leak in the glomerulus in settings of DKD.

Indexed as

AspartameCapillary PermeabilityDiabetic NephropathiesEndothelial CellsEndothelium, VascularHumansIn Vitro TechniquesKidneyMicrovesselsProtective AgentsSaccharinSucroseSweetening AgentsVascular Endothelial Growth FactorsAspartameProtective AgentsSaccharinSucroseSweetening AgentstrichlorosucroseVascular Endothelial Growth Factorsartificial sweetenersdiabetic kidney diseaseendotheliumgas chromatograph-mass spectrometry (GC-MS)glomerularsweet taste receptorvascular endothelial growth factor (VEGF)vascular permeability

Identifiers

PMID34444906
PMCPMC8401733
OpenAlexW3192890851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.